




2023 年法人說明會 Investor Conference









The first manufacturer certified by US FDA and PMDA for injection.

114

Revenue ranks top ten among local pharmaceutical companies. No. 1 market share of sterile injectable products.

Specialized in acute and critical care, nutritional supplements and chemotherapy & oncology Products

● 尚无纪学生主义

Went public market in Jan. 2022.

南光


th

since 1963


A SINCE INCAR

教藥





Production line features



• Plasticizer-free PP plastic infusion bag

南光化學製藥 NANG KUANG PHARMACEUTICAL CO. LTD.

• First manufacturer in Taiwan who use isolator to manufacture products.



International Market Potential
















Search Pharmacies and clinics













To develop CDMO and enter overseas market

Russia

• Antibiotics

Dncology

- Biosimilar drug
- Trace element supplement
 - US

READY TO USE


▲ 點滴・營養 Tenteki Eiyö

- (Developing)












Anti-inflammatory and analgesic drug expert

			INFLAMMA, ANAESTHETIC
Indication	Product	Dosage	ANAESTHETIC P2
Antipyretic	Ibuprofen 4mg/mL, pre-mixed		01023
	Ibuprofen 100mg/mL, Amp.	A	Sales trend of Anti-inflammatory and analgesic products
Antibiotics	Ciprofloxacin		(million) \$60.0 45% Ropivacaine Inj.
	Moxifloxacin		\$50.0 Methylprednisolono Inj. Ciprofloxacin Inj.
	Linezolid		\$40.0 \$30.0 Moxifloxacin Inj.
Painkiller	Ropivacaine 10mg/mL		\$20.0 Linezolid Inj.
Anti- inflammatory	Methylprednisolone for injection		\$10.0 \$0.0
	1		2021 2022 2023(~11月)

Antibiotics against Mycoplasma pneumoniae

南光化學製藥



南光化學教練 NANG KUANG PHARE Expert in Acute and Critical Care


Medicines

Indication	Product	Ready to use	Indication	Product	Ready to use
Antiemetic	Setron class drugs		Vasopressor	Dopamine	
Respiratory Maintenance	Midazolam		Antihyperten sive	Nicardipine	
& Sedation	Dexmedetom idine		ICP Drug	Glycerol	


Acute and Critical Care Medicines

Specialized in acute and critical Care, and nutritional medicines.

Be the leader in the health care field.








- Indication: Sedation, Preoperative Sedation, induction and maintenance of anesthesia
- 5 mg/mL strength is in the <u>leading place</u>.

南光化學製藥

• The Sales volume of 2023 (till Nov.) has been <u>higher</u> than that of 2022.



Nang Kuang IVN Product Strategy Vitamin+Amino Acid - reassure combination







Nutritional Infusion Drop

Newly marketed Unique New Strength Drug


*南光"
諾貝爾美
注射液 500毫克/毫升
10g/20mL

PanNobel-S Injection

500 mg/mL

- ✓ High Dose Vit. C Therapy
- ✓ Vitamin and mineral supplemental therapy (Myer's Cocktail)

PanNobel-S is approved by TFDA in 2023.



More than 1200 medical institutions nationwidely join NK's IVN strategic alliance.




Kinpomin for IV Infusion Glutamine Supplement

Application of Kinpomin Intravenous Nutrition (IVN) in different therapeutic fields:

- General surgery: Repair the postoperative intestinal mucosa and prevent infection
- Oncology : Repair the oral and intestinal mucosa after chemotherapy
- Gastroenterology: repair ulcer
- Dermatology: Whitening
- Hepatitis: Lower the inflammatory index and maintain the liver function
- Others : Anti-aging

Kinpomin is the main ingredient of NK's IVN combinational set, and the rapid sales growth is expected.







- Business model planning (in- and out-patients)
- Pricing strategy and financial planning
- Customized formulation
- development
- Specialty training
- Academic exchanges and visit activities
 - **Real-time Consultation (on-line**





2024 Establish IVN Exhibition Center

in Nangang Global One Guidance

medical institutions to establish

professional INV clinics

- Speed the conclusion of strategic alliance
 - Active marketing to replicate the experiences of success rapidly.

Long-Acting Injectable Products/Platform









ND340 Development Timetable

	2022	2023	2024	2025	2026	2027	2028	2029
1. TW healthy volunteers [Phase I/PK]	Nation	al Taiwa	an Univ	ersity F	lospital	X	<i>.</i>	
2. TW surgery patients [Phase IIa/b]		Seve	al hosp	itals in	Taiwan			
Multinational Phase III [1 st Indication]								
TW NDA		5					V submiss pected in	
Multinational Phase III [2 nd Indication]								7
 NDA USA China Korea 							A submis pected in	· · · · · · · · · · · · · · · · · · ·

There are still several LAIs under development!





CONSOLIDATED BALANCE SHEETS Unit: NT\$ million				
Accounting Title	2023/9/30		2022/9/30	
Current Assets	1,595	41%	1,488	44%
Non-current financial assets at fair value through profit or loss	148	4%	64	2%
Non-current financial assets at amortised cost	157	4%	157	5%
Property, plant and equipment	1,873	49%	1,619	48%
Investment property, net	6	0%	6	0%
Prepayments for equipment	24	1%	7	0%
Other noncurrent assets	40	1%	41	1%
Total Assets	3,843	100%	3,382	100%
Current Liabilities	1,304	34%	993	30%
Long-term bank loans	19	0%	31	1%
Other noncurrent liabilities	108	3%	109	3%
Total liabilities	1,431	37%	1,133	34%
Total equity	2,412	63%	2,249	66%

CONSOLIDATED STATEME	NTS OF COMPRE	CHENSIVE INCOM		۰ ۱۱
Accounting Title	2023/1/1 To 2023/9/30	2023/1/1 To 2023/9/30	2022	¹ \$ million YoY
Total perating revenue	1,634	1,339	1,940	+22%
Gross profit from operations	573	472	695	+21%
Gross Margin	35%	35%	36%	
Total operating expenses	311	273	373	+14%
Net operating income	262	199	322	+32%
Operating Margin	16%	15%	16%	
Total non-operating income and expenses	26	30	89	-13%
Profit	233	190	352	+23%
Total comprehensive income	233	190	353	+23%
Pre-Tax Profit Margin	17%	17%	21%	
Net Profit Margin	14%	14%	18%	
EPS	NT\$2.31	NT\$1.88	NT\$3.49	+23%

Product

Geography

